Moderna has revealed some promising findings on its coronavirus vaccine candidate.
The company said Monday that during the phase one trial of its potential COVID-19 vaccine it has been developing, eight patients developed antibodies at levels that were on par with those who recovered from the virus, Stat News reports.
Moderna described the interim data from this trial as "positive," with Chief Medical Officer Tal Zaks saying that the findings, though early, "substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials."
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Johns Hopkins Bloomberg School of Public Health's Arturo Casadevall told The Washington Post that "the fact that the vaccine elicited neutralizing antibody amounts comparable or higher to those found in convalescent sera [plasma] is very encouraging," although the Post noted that this "represents only a first step in a long process to bring a vaccine to market." But Moderna chief executive Stephane Bancel told the Post that "we are very, very happy," noting "the vaccine was generally safe."
Moderna is moving into phase two of its clinical trials, having received approval from the Food and Drug Administration, and it says the third phase is expected to begin in the summer. Zaks told The New York Times that if all goes well, doses of a vaccine could potentially be available by the end of this year or early next year, and in terms of how many would be ready, he said "we're doing our best to make it as many millions as possible."
-
Fannie Flagg’s 6 favorite books that sparked her imaginationFeature The author recommends works by Johanna Spyri, John Steinbeck, and more
-
Google: A monopoly past its prime?Feature Google’s antitrust case ends with a slap on the wrist as courts struggle to keep up with the tech industry’s rapid changes
-
Patrick Hemingway: The Hemingway son who tended to his father’s legacyFeature He was comfortable in the shadow of his famous father, Ernest Hemingway
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year highSpeed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, changeSpeed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panelspeed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kidsSpeed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sickspeed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last yearspeed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
